Hoje ela usada para obesidade e diabetes, mas sabemos que tem o potencial de, no futuro, poder ser aplicada para o tratamento de cncer e doenas autoimunes, disse Padilha
Factors that predict superior outcomes include aggressive dose escalation , high protein intake, consistent resistance training, perfect medication adherence, and younger age
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
Ludovic Helfgott, a Novo Nordisk executive, told Reuters during the European Association for the Study of Diabetes conference in Vienna: "We always presented it as a lottery ticket and it still is because it's very uncertain." The company is currently investigating whether semaglutide, the active ingredient found in popular medications Ozempic and Wegovy, can effectively slow cognitive decline in patients experiencing early-stage Alzheimers
